Early detection opportunity RetiSpec focuses on AI-based early detection of neurodegenerative diseases through retinal imaging, offering a scalable point-of-care test. Sales teams should position to health systems and eye care networks seeking non-invasive, proactive Alzheimer’s screening to expand preventive care and reduce downstream costs.

Clinical validation path The company is advancing regulatory and market entry plans for its first clinically validated test to predict amyloid burden. Identify opportunities with hospitals, research networks, and payers prioritizing validated screening tools for cognitive decline to support adoption and reimbursement discussions.

Strategic partnerships RetiSpec collaborates with leading hospitals and research networks across North America and has recent board additions from the imaging hardware space. Pursue partnerships with medical centers, optometry practices, and device manufacturers to co-develop deployment pilots and scale field use.

Funding and growth With a Series A of $10M and revenue in the low single to mid single digits, the company is in growth phase and actively expanding capability. Target investors, grant programs, and health system procurement teams looking for AI-driven brain health solutions to support financing and scale.

Market positioning & fit Operating in software for neurodegenerative screening with a relatively lean team, RetiSpec sits near competitors like Optina Diagnostics and G-Metrics. Emphasize differentiators such as non-invasive retinal imaging, point-of-care amyloid prediction, and large hospital study affiliations to win healthcare system procurement and early adopter customers.